ARMP | Ticker Profile - Titan Protect

ARMP

Armata Pharmaceuticals, Inc.

Healthcare · Biotechnology · ASE

$7.50

Data: 2026-05-13

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$326M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-5.66

Based on estimated future earnings — lower means cheaper

Rev Growth

-12.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

0.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.50

+133% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

https://www.armatapharma.com

Country: United States Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

88.4% FAIL

Debt must be below 33% of total assets

Cash Ratio

2.7% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.964

Good returns relative to risk taken

Kelly Fraction

0.0673

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.060

Returns exceed worst-case losses — strong risk profile

Annual Return

77.1%

Historical annualised return based on price data

Max Drawdown

-72.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

119

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$16.34

54% below the year high

52W Low

$1.17

541% above the year low

Avg Volume

56,432

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.1%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.80

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

0.64

Below 1 means short-term obligations exceed liquid assets — risk flag

Quick Ratio

0.52

Like current ratio but excludes inventory — stricter test

Gross Margin

-202.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,113.4%

Profit from core operations before interest and tax

Free Cash Flow

$-26,138,876

Negative — the business is spending more than it generates

Revenue (TTM)

$5M

Total revenue over the last 12 months

Net Income

$-282,614,016

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$17.50

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go